Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Pharmaceutical Treatments for Mental Health Disorders: Global Markets

Published by BCC Research Product code 988629
Published Content info 128 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pharmaceutical Treatments for Mental Health Disorders: Global Markets
Published: February 9, 2021 Content info: 128 Pages
Description

Highlights:

The global market for drugs prescribed to treat mental health disorders should grow from $49.4 billion in 2020 to $62.6 billion by 2025 with a compound annual growth rate (CAGR) of 4.8% for the period of 2020-2025.

ADHD market should grow from $17.8 billion in 2020 to $24.2 billion by 2025 with a compound annual growth rate (CAGR) of 6.3% for the period of 2020-2025.

Depression and anxiety disorders should grow from $14.5 billion in 2020 to $15.8 billion by 2025 with a compound annual growth rate (CAGR) of 1.7% for the period of 2020-2025.

Report Scope:

This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms.

Report Includes:

  • 46 data tables and 12 additional tables
  • An overview of the global markets for pharmaceutical treatments for mental health disorders
  • Analyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
  • Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COIVD-19 pandemic, social distancing and social isolation on the mental health conditions
  • A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
  • Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
  • Information on tele mental health software such as ReSet, Pears Somryst and Alkili's EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
  • Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
  • Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies
  • Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape and their detailed company profiles including, Eli Lilly, Johnson & Johnson, Pfizer, Takeda, and Shionogi
Table of Contents
Product Code: PHM237A

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Depression and Anxiety

  • Market Landscape
  • Segmentation by Drug Class
  • Segmentation by Company
  • Prevalence of Disorders
  • Diagnosis
  • Current Treatments
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
  • Tricyclic Antidepressants (TCAs)
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Atypical Antipsychotics and Second-Generation Antipsychotics (SGAs)
  • Benzodiazepines
  • Recent Drug Developments
  • Drug/Company
  • Late-Stage Drug Failures/Withdrawals
  • Drugs in Clinical Development to Treat Depression
  • Phase 3 Drugs in Development to Treat Depression
  • Phase 2 Drugs in Development to Treat Depression
  • Drugs in Clinical Development to Treat Anxiety
  • Phase 3 Drugs in Development to Treat Anxiety
  • Phase 2 Drugs in Development to Treat Anxiety
  • Alternative Approaches
  • Digital Therapeutics
  • M&A Activity
  • Future Opportunities

Chapter 4 Attention Deficit Hyperactivity Disorder

  • Market Landscape
  • Segmentation by Geography
  • Segmentation by Drug Class
  • Segmentation by Company
  • Prevalence
  • Diagnosis
  • Current Treatments
  • Recent Drug Developments
  • Drugs/Companies
  • Late-Stage Drug Failures/Withdrawals
  • Drugs in Clinical Development to Treat ADHD
  • Phase 3 Drugs in Development to Treat ADHD
  • Phase 2 Drugs in Development to Treat ADHD
  • Alternative Approaches
  • Digital Therapeutics
  • M&A Activity
  • Future Opportunities

Chapter 5 Schizophrenia

  • Market Landscape
  • Segmentation by Geography
  • Segmentation by Drug Class
  • Segmentation by Company
  • Prevalence
  • Diagnosis
  • Current Treatments
  • Recent Drug Developments
  • Drugs/Companies
  • Late-Stage Drug Failures/Withdrawals
  • Drugs in Clinical Development to Treat Schizophrenia
  • Phase 3 Drugs in Development to Treat Schizophrenia
  • Phase 2 Drugs in Development to Treat Schizophrenia
  • Alternative Approaches
  • Digital Therapeutics
  • M&A Activity
  • Future Opportunities

Chapter 6 Substance Use Disorders

  • Market Landscape
  • Segmentation by Geography
  • Segmentation by Drug Class
  • Segmentation by Company
  • Prevalence
  • Diagnosis
  • Current Treatments
  • Opioid Use Disorders
  • Alcohol Use Disorders
  • Nicotine Use Disorders
  • Recent Drug Developments
  • Drugs in Clinical Development to Substance Abuse Disorder
  • Phase 3 Drugs in Development to Treat Substance Use Disorders
  • Phase 2 Drugs in Development to Treat Substance Use Disorder
  • Alternative Approaches
  • Digital Therapeutics
  • M&A Activity
  • Future Opportunities

Chapter 7 Company Profiles

  • Pharmaceutical Companies
  • ABBVIE
  • ALKERMES PLC
  • ASTRAZENECA PLC
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • ELI LILLY & CO.
  • GLAXOSMITHKLINE PLC
  • H LUNDBECK A/S
  • JOHNSON & JOHNSON
  • OTSUKA HOLDINGS CO. LTD.
  • PFIZER INC.
  • SHIONOGI & CO. LTD.
  • TAKEDA PHARMACEUTICALS CO. LTD.
  • Specialty Pharma and Biotechs
  • ACADIA PHARMACEUTICALS INC.
  • ADAMIS PHARMACEUTICALS CORP.
  • BIOXCEL THERAPEUTICS INC.
  • INTRA-CELLULAR THERAPIES INC.
  • INTERVEXION THERAPEUTICS
  • IRONSHORE PHARMACEUTICALS
  • KEMPHARM INC.
  • MINERVA NEUROSCIENCES INC.
  • NEOS THERAPEUTICS INC.
  • NLS PHARMACEUTICAL AG
  • NOVEN PHARMACEUTICALS INC.
  • SAGE THERAPEUTICS
  • SUPERNUS PHARMACEUTICALS, INC.
  • TONIX PHARMACEUTICALS HOLDINGS CORP.
  • TRIS PHARMA INC.
  • Digital Therapeutic Companies
  • OREXO AB
  • PEAR THERAPEUTICS

List of Tables

  • Summary Table : Global Market for Drugs Prescribed to Treat Mental Health Disorders, by Type of Disorder, Through 2025
  • Table 1 : Drugs in Phase 3 Development for Selected Psychiatric Disorders
  • Table 2 : Global Market for Drugs Prescribed to Treat Depression and Anxiety, Through 2025
  • Table 3 : Global Market for Brand Name Drugs Prescribed to Treat Depression and Anxiety, by Leading Drug/Company, Through 2025
  • Table 4 : Global Market for Drugs Prescribed to Treat Depression and Anxiety, by Leading Company/Manufacturer
  • Table 5 : Drug Profiles of Leading Approved Antidepressants
  • Table 6 : Drugs Recommended for the Treatment of Anxiety
  • Table 7 : Drugs in Clinical Development to Treat Depression
  • Table 8 : Global Market for New Drugs Prescribed to Treat Depression, by Drug/Company, Through 2025
  • Table 9 : Drugs in Clinical Development to Treat Anxiety Disorders
  • Table 10 : Global Market for New Brand Name Drugs Prescribed to Treat Anxiety, by Drug/Company
  • Table 11 : Global Market for Digital Therapeutics, by Drug/Company, Through 2025
  • Table 12 : Digital Therapeutics in Clinical Development for CNS Disorders
  • Table 13 : Global Market for Drugs Prescribed to Treat Depression and Anxiety, Through 2025
  • Table 14 : Global Market for Drugs Prescribed to Treat ADHD, Through 2025
  • Table 15 : Global Market for Drugs Prescribed to Treat ADHD, by Region, Through 2025
  • Table 16 : Global Market for Leading Brand Name Drugs Prescribed to Treat ADHD, by Drug/Company, Through 2025
  • Table 17 : Global Market for Drugs Prescribed to Treat ADHD, by Leading Company/Manufacturer, Through 2025
  • Table 18 : Drug Profiles of Leading Approved ADHD Treatments
  • Table 19 : ADHD Drug Profiles
  • Table 20 : Drugs in Clinical Development to Treat ADHD
  • Table 21 : Global Market for New Drugs Prescribed to Treat ADHD, by Drug/Company, Through 2025
  • Table 22 : Global Market for Digital Therapeutics, Through 2025
  • Table 23 : Global Market for Drugs Prescribed to Treat ADHD, Through 2025
  • Table 24 : Global Market for Drugs Prescribed to Treat Schizophrenia, Through 2025
  • Table 25 : Global Market for Drugs Prescribed to Treat Schizophrenia, by Region, Through 2025
  • Table 26 : Global Market for Leading Brand Name Drugs Prescribed to Treat Schizophrenia, by Drug/Company, Through 2025
  • Table 27 : Global Market for Drugs Prescribed to Treat Schizophrenia, by Leading Company, Through 2025
  • Table 28 : Drugs in Clinical Development to Treat Schizophrenia
  • Table 29 : Drugs in Clinical Development to Treat Bipolar Disorder
  • Table 30 : Global Market for New Drugs Prescribed to Treat Schizophrenia, Through 2025
  • Table 31 : Global Market for Digital Therapeutics to Treat Schizophrenia, Through 2025
  • Table 32 : Global Market for Drugs Prescribed to Treat Schizophrenia, Through 2025
  • Table 33 : Global Market for Drugs Prescribed to Treat Substance Use Disorders, Through 2025
  • Table 34 : Global Market for Drugs Prescribed to treat Substance Use Disorders, by Region, Through 2025
  • Table 35 : Global Market for Leading Brand Name Drugs Prescribed to Treat Substance Use Disorders, by Drug/Company, Through 2025
  • Table 36 : Global Market for Drugs Prescribed to Treat Substance Use Disorders, by Leading Company, Through 2025
  • Table 37 : Prevalence of Substance Use Disorders across the Globe, by Economy, 1990 vs. 2017
  • Table 38 : Drugs in Clinical Development to Treat Substance Use Disorder
  • Table 39 : Global Market for New Drugs to Treat Substance Abuse Disorders, by Drug/Company Through 2025
  • Table 40 : Global Market for Digital Therapeutics, by Drug/Company, 2019-2025
  • Table 41 : Global Market for Drugs Precribed to Treat Substance Use Disorders, Through 2025
  • Table 42 : AbbVie Revenue, 2017-2020
  • Table 43 : Alkermes Revenue, 2017-2020
  • Table 44 : AstraZeneca Revenue, 2017-2020
  • Table 45 : Boehringer Ingelheim Revenue, 2019
  • Table 46 : Eli Lilly Revenue, 2017-2020
  • Table 47 : GlaxoSmithKline Revenue, 2017-2020
  • Table 48 : H Lundbeck A/S Revenue, 2017-2020
  • Table 49 : Johnson & Johnson Revenue, 2017-2020
  • Table 50 : Otsuka Revenue, 2017-2020
  • Table 51 : Pfizer Revenue, 2017-2020
  • Table 52 : Shionogi Revenue, Through 2019
  • Table 53 : Takeda Revenue, 2017-2020
  • Table 54 : ACADIA Pharmaceuticals Revenue, 2017-2020
  • Table 55 : Supernus Pharmaceuticals Revenue, 2017-2020
  • Table 56 : Tonix Pharmaceuticals Revenues, 2017-2020
  • Table 57 : Orexo Therapeutics Revenue, Through 2019

List of Figures

  • Summary Figure : Global Market for Drugs Prescribed to Treat Mental Health Disorders, by Type of Disorder, 2019-2025
  • Figure 1 : Prevalence of Depressive Disorders, by Region
  • Figure 2 : Prevalence of Anxiety Disorders, by Region
  • Figure 3 : AXS-05 Mechanism of Action
  • Figure 4 : DSM Criteria for ADHD
  • Figure 5 : Prevalence of ADHD Subtypes, by Age Group
  • Figure 6 : Development Timelines of Leading ADHD Drugs
  • Figure 7 : Prevalence of Schizophrenia Population, by Sex
  • Figure 8 : Share of the Population with an Alcohol or Drug Use Disorder, 2016
  • Figure 9 : People with Substance Use Disorder and Mental Health Disorder
Back to Top